Literature DB >> 11193598

Effects of Clostridium difficile toxins on epithelial cell barrier.

C Pothoulakis1.   

Abstract

Clostridium difficile is the primary agent responsible for many patients with antibiotic-associated diarrhea and almost all patients with pseudomembranous colitis following antibiotic therapy. C. difficile infection is the most frequent form of colitis in hospitals and nursing homes and affects millions of patients in the United States and abroad. The first event in the pathogenesis of C. difficile infection involves alterations of the indigenous colonic microflora by antibiotics, followed by colonization with C. difficile. C. difficile causes diarrhea and colitis by releasing two high molecular weight protein exotoxins, toxin A and toxin B, with potent cytotoxic and enterotoxic properties. Evidence presented here indicates that C. difficile toxins compromise the epithelial cell barrier by at least two pathophysiologic pathways, one involving disaggregation of actin microfilaments in colonocytes via glucosylation of the Rho family of proteins leading to epithelial cell destruction and opening of the tight junctions, whereas the other appears to involve early release of proinflammatory cytokines from intestinal epithelial cells probably via activation of MAP kinases. We speculate that cytokines released from intestinal epithelial cells in response to toxin A exposure will diffuse into the lamina propria and activate macrophages, enteric nerves, and sensory neurons to release SP, CGRP, and NT, which, in turn, interact with immune and inflammatory cells and amplify the inflammatory response. Dissection of this inflammatory cascade may help us understand the pathophysiology of inflammatory diarrhea caused by this important pathogen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11193598     DOI: 10.1111/j.1749-6632.2000.tb05263.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  33 in total

1.  Transcriptional profiling of Clostridium difficile and Caco-2 cells during infection.

Authors:  Tavan Janvilisri; Joy Scaria; Yung-Fu Chang
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

Review 2.  Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void?

Authors:  David Brown
Journal:  Nat Rev Drug Discov       Date:  2015-10-23       Impact factor: 84.694

3.  Human milk oligosaccharides protect bladder epithelial cells against uropathogenic Escherichia coli invasion and cytotoxicity.

Authors:  Ann E Lin; Chloe A Autran; Sophia D Espanola; Lars Bode; Victor Nizet
Journal:  J Infect Dis       Date:  2013-08-29       Impact factor: 5.226

4.  Clostridium sordellii lethal toxin kills mice by inducing a major increase in lung vascular permeability.

Authors:  Blandine Geny; Huot Khun; Catherine Fitting; Leticia Zarantonelli; Christelle Mazuet; Nadège Cayet; Marek Szatanik; Marie-Christine Prevost; Jean-Marc Cavaillon; Michel Huerre; Michel R Popoff
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

5.  Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity.

Authors:  Glen C Ulett; Elisabeth E Adderson
Journal:  Curr Immunol Rev       Date:  2006-05

6.  A new role for heat shock factor 27 in the pathophysiology of Clostridium difficile toxin B.

Authors:  Murali K Yanda; William B Guggino; Liudmila Cebotaru
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-11-11       Impact factor: 4.052

7.  Clostridium difficile toxin A promotes dendritic cell maturation and chemokine CXCL2 expression through p38, IKK, and the NF-kappaB signaling pathway.

Authors:  Jin Young Lee; Hyunah Kim; Mi Yeon Cha; Hong Gyu Park; Young-Jeon Kim; In Young Kim; Jung Mogg Kim
Journal:  J Mol Med (Berl)       Date:  2008-11-05       Impact factor: 4.599

8.  Melanin-concentrating hormone (MCH) modulates C difficile toxin A-mediated enteritis in mice.

Authors:  E Kokkotou; D O Espinoza; D Torres; I Karagiannides; S Kosteletos; T Savidge; M O'Brien; C Pothoulakis
Journal:  Gut       Date:  2008-09-29       Impact factor: 23.059

9.  Recombinant Mucin-Type Fusion Proteins with a Galα1,3Gal Substitution as Clostridium difficile Toxin A Inhibitors.

Authors:  Reeja Maria Cherian; Chunsheng Jin; Jining Liu; Niclas G Karlsson; Jan Holgersson
Journal:  Infect Immun       Date:  2016-09-19       Impact factor: 3.441

10.  Recombinant single-chain variable fragment antibodies directed against Clostridium difficile toxin B produced by use of an optimized phage display system.

Authors:  Xiao K Deng; Lance A Nesbit; K John Morrow
Journal:  Clin Diagn Lab Immunol       Date:  2003-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.